| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
PCI-34051 is a novel, potent and specific inhibitor of histone deacetylase 8 (HDAC8) with potential anticancer activity. It exhibits >200-fold selectivity for HDAC8 over HDAC1 and 6, and 1000-fold higher selectivity over HDAC2/3/10. In a cell-free assay, it inhibits HDAC8 with an IC50 of 10 nM.
| Targets |
HDAC8 ( IC50 = 10 nM ); HDAC6 ( IC50 = 2.9 μM ); HDAC1 ( IC50 = 4 μM ); HDAC10 ( IC50 = 13 μM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
Measurements are conducted in a reaction volume of 100 μL using 96-well assay plates in a fluorescence plate reader for PCI-34051 characterization. for every isozyme. The HDAC protein is combined with PCI-34051 at different concentrations and incubated for 15 minutes in reaction buffer (50 mM HEPES, 100 mM KCl, 0.001% Tween-20, 5% dimethyl sulfoxide, pH7.4) supplemented with bovine serum albumin at concentrations of 0-0.05%. The reaction is started by adding acetyl-gly-Ala-(N-acetyl-Lys)-amino-4-methylcoumarin at a final concentration of 25–100 μM and trysin at a final concentration of 50 nM. The fluorescence is measured over a 30-minute period with an excitation wavelength of 335 nm and a detection wavelength of 460 nm, following a 30-minute lag time. The reaction rate is determined by measuring the increase in fluorescence with time.
|
|
| Cell Assay |
Human umbilical vein endothelial cells and tumor cell lines are cultured for at least two doubling times, and growth is assessed using an Alamar Blue fluorometric cell proliferation assay, per the manufacturer's recommendation, at the conclusion of PCI-34051 exposure. In 96-well plates, PCI-34051 is tested in triplicate wells. A logistic equation with four parameters is used to estimate the concentration needed to inhibit cell growth by 50% (GI50) and the 95% confidence intervals from nonlinear regression.
|
|
| Animal Protocol |
|
|
| References |
| Molecular Formula |
C17H16N2O3
|
|
|---|---|---|
| Molecular Weight |
296.32
|
|
| Exact Mass |
296.12
|
|
| Elemental Analysis |
C, 68.91; H, 5.44; N, 9.45; O, 16.20
|
|
| CAS # |
950762-95-5
|
|
| Related CAS # |
|
|
| Appearance |
White to gray solid powder
|
|
| SMILES |
COC1=CC=C(C=C1)CN2C=CC3=C2C=C(C=C3)C(=O)NO
|
|
| InChi Key |
AJRGHIGYPXNABY-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C17H16N2O3/c1-22-15-6-2-12(3-7-15)11-19-9-8-13-4-5-14(10-16(13)19)17(20)18-21/h2-10,21H,11H2,1H3,(H,18,20)
|
|
| Chemical Name |
N-hydroxy-1-[(4-methoxyphenyl)methyl]indole-6-carboxamide
|
|
| Synonyms |
PCI-34051; PCI 34051; PCI34051
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 30% PEG400+0.5% Tween80+5% propylene glycol: 30mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3747 mL | 16.8737 mL | 33.7473 mL | |
| 5 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL | |
| 10 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
